Phaseline

Companies › Shanghai Jiatan Pharmatech

Shanghai Jiatan Pharmatech: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Infectious disease, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sudapyridine (WX-081)
Tuberculosis antibiotic - mechanism of action not specified in trial registry
–Phase 3Rifampin-Resistant Pulmonary Tuberculosis; TB–
WX390
STK11 inhibitor
STK11Phase 2Gastric Type Adenocarcinoma (GAS) With STK11 Mutation; Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06117566WX390Phase 1Solid TumorOncologyNov 2025
NCT06701110Sudapyridine (WX-081)Phase 1TBInfectious diseaseDec 2025
NCT05824871Sudapyridine (WX-081)Phase 3Rifampin-Resistant Pulmonary TuberculosisInfectious diseaseDec 2025
NCT06124963WX390Phase 2Gastric Type Adenocarcinoma (GAS) With STK11 MutationOncologyDec 2026

Targets

STK11 (1)

Companies with the same targets

–

Companies built like this

Shanghai Bovax Biotechnology Cantex Pharmaceuticals The Skin Center Dermatology Group Tetraphase Pharmaceuticals Amivas

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.